Atea Pharmaceuticals to Host Third Quarter 2023 Financial Results Conference Call on November 8, 2023GlobeNewsWire • 11/01/23
Atea Pharmaceuticals to Present at the Morgan Stanley 21st Annual Global Healthcare ConferenceGlobeNewsWire • 09/06/23
Atea Pharmaceuticals Reports Second Quarter 2023 Financial Results and Provides Business UpdateGlobeNewsWire • 08/08/23
Atea Pharmaceuticals to Host Second Quarter 2023 Financial Results Conference Call on August 8, 2023GlobeNewsWire • 08/01/23
Atea Pharmaceuticals' Board of Directors Unanimously Rejects Unsolicited Proposal from Tang Capital Partners' Affiliate, Concentra BiosciencesGlobeNewsWire • 05/30/23
Atea Pharmaceuticals Confirms Receipt of Unsolicited Proposal from Tang Capital Partners' Affiliate, Concentra BiosciencesGlobeNewsWire • 05/23/23
Atea Pharmaceuticals Reports First Quarter 2023 Financial Results and Provides Business UpdateGlobeNewsWire • 05/08/23
Atea Pharmaceuticals to Host First Quarter 2023 Financial Results Conference Call on May 8, 2023GlobeNewsWire • 05/01/23
Atea Pharmaceuticals Announces U.S. FDA Fast Track Designation Granted to Bemnifosbuvir, an Investigational Oral Antiviral, for the Treatment of COVID-19GlobeNewsWire • 04/25/23
Atea Announces Presentation of Bemnifosbuvir Data Demonstrating Reduced Hospitalizations for COVID-19 Patients at 2023 European Congress of Clinical Microbiology & Infectious DiseasesGlobeNewsWire • 04/12/23
New Data Showcasing Favorable Profile of Bemnifosbuvir for Treatment of COVID-19 and Hepatitis C Presented at 2023 International Conference on Antiviral ResearchGlobeNewsWire • 03/14/23
New Data Showcasing Favorable Profile of Bemnifosbuvir for Treatment of COVID-19 and Hepatitis C to be Presented at 2023 International Conference on Antiviral ResearchGlobeNewsWire • 03/08/23
Atea Pharmaceuticals Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business UpdateGlobeNewsWire • 02/28/23
Atea Pharmaceuticals Presents Favorable Drug Interaction Profile of Bemnifosbuvir in Phase 1 Studies at CROI 2023GlobeNewsWire • 02/23/23
Atea Pharmaceuticals to Report Fourth Quarter and Full Year 2022 Financial Results and Provide Business Update on February 28, 2023GlobeNewsWire • 02/21/23
Atea Pharmaceuticals to Present Data on Bemnifosbuvir Drug Interaction Profile at Conference on Retroviruses and Opportunistic InfectionsGlobeNewsWire • 02/15/23
Atea Pharmaceuticals to Present at the SVB Securities Global Biopharma ConferenceGlobeNewsWire • 02/07/23
Atea Pharmaceuticals to Present at the 41st Annual J.P. Morgan Healthcare ConferenceGlobeNewsWire • 01/04/23
Atea Pharmaceuticals Announces First Patient Dosed in SUNRISE-3 Phase 3 Registrational Trial of Bemnifosbuvir, an Investigational Oral Antiviral for the Treatment of COVID-19GlobeNewsWire • 11/29/22
Atea Pharmaceuticals to Present at the 5th Annual Evercore ISI HealthCONx ConferenceGlobeNewsWire • 11/22/22
Atea Pharmaceuticals, Inc. (AVIR) Moves to Buy: Rationale Behind the UpgradeZacks Investment Research • 11/10/22
After Plunging 10.6% in 4 Weeks, Here's Why the Trend Might Reverse for Atea Pharmaceuticals, Inc. (AVIR)Zacks Investment Research • 11/10/22